248 related articles for article (PubMed ID: 22990019)
21. Frequency, distribution, and immunomorphologic characteristics of peripheral T-cell lymphoma, not otherwise specified in a tertiary care center in Southern India.
Lakshmanan A; Sikri D; Patil S; Kurian A; Annapurneswari S; Nair S
Indian J Pathol Microbiol; 2018; 61(2):204-208. PubMed ID: 29676358
[TBL] [Abstract][Full Text] [Related]
22. Expression of follicular helper T cell markers in nodal peripheral T cell lymphomas: a tissue microarray analysis of 162 cases.
Zhan HQ; Li XQ; Zhu XZ; Lu HF; Zhou XY; Chen Y
J Clin Pathol; 2011 Apr; 64(4):319-24. PubMed ID: 21330314
[TBL] [Abstract][Full Text] [Related]
23. Comparison of clinicopathological characteristics between T-cell prolymphocytic leukemia and peripheral T-cell lymphoma, not otherwise specified.
Kawamoto K; Miyoshi H; Yanagida E; Yoshida N; Kiyasu J; Kozai Y; Morikita T; Kato T; Suzushima H; Tamura S; Muta T; Kato K; Eto T; Seki R; Nagafuji K; Sone H; Takizawa J; Seto M; Ohshima K
Eur J Haematol; 2017 May; 98(5):459-466. PubMed ID: 28129454
[TBL] [Abstract][Full Text] [Related]
24. Pathobiology and molecular profiling of peripheral T-cell lymphomas.
de Leval L; Gaulard P
Hematology Am Soc Hematol Educ Program; 2008; ():272-9. PubMed ID: 19074096
[TBL] [Abstract][Full Text] [Related]
25. Clinicopathological features of programmed cell death-1 and programmed cell death-ligand-1 expression in the tumor cells and tumor microenvironment of angioimmunoblastic T cell lymphoma and peripheral T cell lymphoma not otherwise specified.
Kim S; Kwon D; Koh J; Nam SJ; Kim YA; Kim TM; Kim CW; Jeon YK
Virchows Arch; 2020 Jul; 477(1):131-142. PubMed ID: 32170448
[TBL] [Abstract][Full Text] [Related]
26. Clinical and prognostic differences between ALK-negative anaplastic large cell lymphoma and peripheral T cell lymphoma, not otherwise specified: a single institution experience.
Deng XW; Zhang XM; Wang WH; Wang SL; Jin J; Fang H; Ren H; Liu YP; He XH; Dong M; Song YW; Li YX
Ann Hematol; 2016 Aug; 95(8):1271-80. PubMed ID: 27209536
[TBL] [Abstract][Full Text] [Related]
27. The clinical significance of activated p-AKT expression in peripheral T-cell lymphoma.
Hong JY; Hong ME; Choi MK; Chang W; Do IG; Jo JS; Jung SH; Park S; Kim SJ; Ko YH; Kim WS
Anticancer Res; 2015 Apr; 35(4):2465-74. PubMed ID: 25862915
[TBL] [Abstract][Full Text] [Related]
28. Microenvironmental immune cell signatures dictate clinical outcomes for PTCL-NOS.
Sugio T; Miyawaki K; Kato K; Sasaki K; Yamada K; Iqbal J; Miyamoto T; Ohshima K; Maeda T; Miyoshi H; Akashi K
Blood Adv; 2018 Sep; 2(17):2242-2252. PubMed ID: 30194138
[TBL] [Abstract][Full Text] [Related]
29. Integration of transcriptional and mutational data simplifies the stratification of peripheral T-cell lymphoma.
Maura F; Agnelli L; Leongamornlert D; Bolli N; Chan WC; Dodero A; Carniti C; Heavican TB; Pellegrinelli A; Pruneri G; Butler A; Bhosle SG; Chiappella A; Di Rocco A; Zinzani PL; Zaja F; Piva R; Inghirami G; Wang W; Palomero T; Iqbal J; Neri A; Campbell PJ; Corradini P
Am J Hematol; 2019 Jun; 94(6):628-634. PubMed ID: 30829413
[TBL] [Abstract][Full Text] [Related]
30. Profiles of serum cytokines and their clinical implications in patients with peripheral T-cell lymphoma.
Yi JH; Ryu KJ; Ko YH; Kim WS; Kim SJ
Cytokine; 2019 Jan; 113():371-379. PubMed ID: 30327172
[TBL] [Abstract][Full Text] [Related]
31. Peripheral T-cell lymphoma with a T follicular-helper phenotype: A different entity? Results of the Spanish Real-T study.
Martín García-Sancho A; Rodríguez-Pinilla SM; Domingo-Domenech E; Climent F; Sánchez-Garcia J; López Jiménez J; García-Cosío Piqueras M; Castellvi J; González AJ; González de Villambrosia S; Gómez Codina J; Navarro B; Rodríguez G; Borrero JJ; Fraga M; Naves A; Baeza L; Córdoba R
Br J Haematol; 2023 Oct; 203(2):182-193. PubMed ID: 37386897
[TBL] [Abstract][Full Text] [Related]
32. Reproducing the molecular subclassification of peripheral T-cell lymphoma-NOS by immunohistochemistry.
Amador C; Greiner TC; Heavican TB; Smith LM; Galvis KT; Lone W; Bouska A; D'Amore F; Pedersen MB; Pileri S; Agostinelli C; Feldman AL; Rosenwald A; Ott G; Mottok A; Savage KJ; de Leval L; Gaulard P; Lim ST; Ong CK; Ondrejka SL; Song J; Campo E; Jaffe ES; Staudt LM; Rimsza LM; Vose J; Weisenburger DD; Chan WC; Iqbal J
Blood; 2019 Dec; 134(24):2159-2170. PubMed ID: 31562134
[TBL] [Abstract][Full Text] [Related]
33. Peripheral T-cell lymphoma with follicular T-cell markers.
Rodríguez-Pinilla SM; Atienza L; Murillo C; Pérez-Rodríguez A; Montes-Moreno S; Roncador G; Pérez-Seoane C; Domínguez P; Camacho FI; Piris MA
Am J Surg Pathol; 2008 Dec; 32(12):1787-99. PubMed ID: 18779728
[TBL] [Abstract][Full Text] [Related]
34. Peripheral T-cell lymphoma--not otherwise specified.
Savage KJ; Ferreri AJ; Zinzani PL; Pileri SA
Crit Rev Oncol Hematol; 2011 Sep; 79(3):321-9. PubMed ID: 20702104
[TBL] [Abstract][Full Text] [Related]
35. [Expressions of CXCL13, CD10 and bcl-6 in angioimmunoblastic T-cell lymphoma and peripheral T-cell lymphoma, not otherwise specified].
Tang XF; Li GD; Li YL; Liang DN; Xia T; Zhou JY; Yao YQ; Wu WQ; Wang ZG; Yang YH; Tang XB; Bai YQ; Ding Q
Zhonghua Bing Li Xue Za Zhi; 2009 Apr; 38(4):224-30. PubMed ID: 19575892
[TBL] [Abstract][Full Text] [Related]
36. Outcome of combined modality treatment in first-line for stage I(E) peripheral T-cell lymphoma; a nationwide population-based cohort study from the Netherlands.
Meeuwes FO; Brink M; Plattel W; Van der Poel MWM; Kersten MJ; Wondergem M; Böhmer L; Woei-A-Jin FJSH; Visser O; Oostvogels R; Jansen PM; Neelis KJ; Crijns APG; Daniëls LA; Snijders TJF; Vermaat JSP; Huls GA; Nijland M
Haematologica; 2024 Apr; 109(4):1163-1170. PubMed ID: 37794805
[TBL] [Abstract][Full Text] [Related]
37. Prognostic and therapeutic significance of phosphorylated STAT3 and protein tyrosine phosphatase-6 in peripheral-T cell lymphoma.
Han JJ; O'byrne M; Stenson MJ; Maurer MJ; Wellik LE; Feldman AL; McPhail ED; Witzig TE; Gupta M
Blood Cancer J; 2018 Nov; 8(11):110. PubMed ID: 30420593
[TBL] [Abstract][Full Text] [Related]
38. Large cell morphology, CMYC+ tumour cells, and PD-1+ tumour cell/intense PD-L1+ cell reactions are important prognostic factors in nodal peripheral T-cell lymphomas with T follicular helper markers.
Mihashi Y; Kimura S; Iwasaki H; Oshiro Y; Takamatsu Y; Kawauchi S; Shimajiri S; Ishizuka K; Takeshita M
Diagn Pathol; 2021 Nov; 16(1):101. PubMed ID: 34742294
[TBL] [Abstract][Full Text] [Related]
39. Genomic signatures in T-cell lymphoma: How can these improve precision in diagnosis and inform prognosis?
Iqbal J; Wilcox R; Naushad H; Rohr J; Heavican TB; Wang C; Bouska A; Fu K; Chan WC; Vose JM
Blood Rev; 2016 Mar; 30(2):89-100. PubMed ID: 26319391
[TBL] [Abstract][Full Text] [Related]
40. Molecular Insights Into Pathogenesis of Peripheral T Cell Lymphoma: a Review.
Lone W; Alkhiniji A; Manikkam Umakanthan J; Iqbal J
Curr Hematol Malig Rep; 2018 Aug; 13(4):318-328. PubMed ID: 29951889
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
